Loading...

WuXi Biologics (Cayman)

DB:1FW
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1FW
DB
HK$87B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

WuXi Biologics (Cayman) Inc., an investment holding company, provides discovery, research, development, and manufacturing of biologics services. The last earnings update was 25 days ago. More info.


Add to Portfolio Compare Print
1FW Share Price and Events
7 Day Returns
-5.2%
DB:1FW
2.5%
Europe Life Sciences
0.3%
DE Market
1 Year Returns
-5%
DB:1FW
17%
Europe Life Sciences
-11.6%
DE Market
1FW Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
WuXi Biologics (Cayman) (1FW) -5.2% -11.8% 3.4% -5% - -
Europe Life Sciences 2.5% 7% 11.9% 17% 74.1% 194.3%
DE Market 0.3% -3.8% 2.5% -11.6% 10.1% 7.9%
1 Year Return vs Industry and Market
  • 1FW underperformed the Life Sciences industry which returned 17% over the past year.
  • 1FW outperformed the Market in Germany which returned -11.6% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is WuXi Biologics (Cayman) undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of WuXi Biologics (Cayman) to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for WuXi Biologics (Cayman).

DB:1FW Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 14 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:1FW
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.02
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.016 (1 + (1- 25%) (0%))
1.01
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.01
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.01 * 5.96%)
6.25%

Discounted Cash Flow Calculation for DB:1FW using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for WuXi Biologics (Cayman) is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:1FW DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CNY, Millions) Source Present Value
Discounted (@ 6.25%)
2019 -2,707.63 Analyst x8 -2,548.35
2020 30.67 Analyst x6 27.16
2021 1,601.20 Analyst x5 1,334.93
2022 2,464.51 Analyst x4 1,933.82
2023 3,940.00 Analyst x3 2,909.73
2024 5,214.33 Est @ 32.34% 3,624.32
2025 6,398.44 Est @ 22.71% 4,185.76
2026 7,419.93 Est @ 15.96% 4,568.47
2027 8,254.19 Est @ 11.24% 4,783.18
2028 8,909.49 Est @ 7.94% 4,859.22
Present value of next 10 years cash flows CN¥25,678.24
DB:1FW DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= CN¥8,909.49 × (1 + 0.23%) ÷ (6.25% – 0.23%)
CN¥148,288.11
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CN¥148,288.11 ÷ (1 + 6.25%)10
CN¥80,876.05
DB:1FW Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CN¥25,678.24 + CN¥80,876.05
CN¥106,554.29
Equity Value per Share
(CNY)
= Total value / Shares Outstanding
= CN¥106,554.29 / 1,229.92
CN¥756.43
DB:1FW Discount to Share Price
Calculation Result
Exchange Rate CNY/HKD
(Reporting currency to currency of SEHK:2269)
1.137
Value per Share
(HKD)
= Value per Share in CNY x Exchange Rate (CNY/HKD)
= CN¥86.64 x 1.137
HK$98.53
Non-primary Listing Adjustment Factor 1 share in DB:1FW represents 0.11453x of SEHK:2269
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.11453x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (HKD) x Listing Adjustment Factor
= HK$ 98.53 x 0.11453
€11.29
Value per share (EUR) From above. €11.29
Current discount Discount to share price of €8.06
= -1 x (€8.06 - €11.29) / €11.29
28.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price WuXi Biologics (Cayman) is available for.
Intrinsic value
29%
Share price is €8.06 vs Future cash flow value of €11.29
Current Discount Checks
For WuXi Biologics (Cayman) to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • WuXi Biologics (Cayman)'s share price is below the future cash flow value, and at a moderate discount (> 20%).
  • WuXi Biologics (Cayman)'s share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for WuXi Biologics (Cayman)'s earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are WuXi Biologics (Cayman)'s earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1FW PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in CNY CN¥0.52
SEHK:2269 Share Price ** SEHK (2019-05-21) in HKD HK$70.4
SEHK:2269 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.879 CN¥61.9
Europe Life Sciences Industry PE Ratio Median Figure of 16 Publicly-Listed Life Sciences Companies 39.72x
Germany Market PE Ratio Median Figure of 423 Publicly-Listed Companies 20.29x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of WuXi Biologics (Cayman).

DB:1FW PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:2269 Share Price ÷ EPS (both in CNY)

= 61.9 ÷ 0.52

118.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • WuXi Biologics (Cayman) is overvalued based on earnings compared to the Europe Life Sciences industry average.
  • WuXi Biologics (Cayman) is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does WuXi Biologics (Cayman)'s expected growth come at a high price?
Raw Data
DB:1FW PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 118.83x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts
29.1%per year
Europe Life Sciences Industry PEG Ratio Median Figure of 12 Publicly-Listed Life Sciences Companies 2.75x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.5x

*Line of best fit is calculated by linear regression .

DB:1FW PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 118.83x ÷ 29.1%

4.08x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • WuXi Biologics (Cayman) is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on WuXi Biologics (Cayman)'s assets?
Raw Data
DB:1FW PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in CNY CN¥6.52
SEHK:2269 Share Price * SEHK (2019-05-21) in HKD HK$70.4
SEHK:2269 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.879 CN¥61.9
Europe Life Sciences Industry PB Ratio Median Figure of 36 Publicly-Listed Life Sciences Companies 2.89x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.79x
DB:1FW PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:2269 Share Price ÷ Book Value per Share (both in CNY)

= 61.9 ÷ 6.52

9.49x

* Primary Listing of WuXi Biologics (Cayman).

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • WuXi Biologics (Cayman) is overvalued based on assets compared to the Europe Life Sciences industry average.
X
Value checks
We assess WuXi Biologics (Cayman)'s value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. WuXi Biologics (Cayman) has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is WuXi Biologics (Cayman) expected to perform in the next 1 to 3 years based on estimates from 14 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
29.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is WuXi Biologics (Cayman) expected to grow at an attractive rate?
  • WuXi Biologics (Cayman)'s earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • WuXi Biologics (Cayman)'s earnings growth is expected to exceed the Germany market average.
  • WuXi Biologics (Cayman)'s revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1FW Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1FW Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts 29.1%
DB:1FW Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 14 Analysts 27.6%
Europe Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 14.2%
Europe Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1FW Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1FW Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 12,679 4,624 4,227 5
2022-12-31 10,040 2,966 3,115 6
2021-12-31 7,545 2,780 2,172 11
2020-12-31 5,721 1,844 1,509 14
2019-12-31 3,937 1,712 989 13
DB:1FW Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2018-12-31 2,534 762 631
2018-09-30 2,277 508 520
2018-06-30 2,019 255 410
2018-03-31 1,819 308 331
2017-12-31 1,619 360 253
2017-09-30 1,429 320 177
2017-06-30 1,233 369 149
2017-03-31 1,111 226 145
2016-12-31 989 82 141
2016-09-30 889 162 171

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • WuXi Biologics (Cayman)'s earnings are expected to grow significantly at over 20% yearly.
  • WuXi Biologics (Cayman)'s revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1FW Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below

All data from WuXi Biologics (Cayman) Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1FW Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.09 3.09 3.09 1.00
2022-12-31 2.44 2.58 2.30 2.00
2021-12-31 1.66 2.19 1.20 10.00
2020-12-31 1.14 1.44 0.94 13.00
2019-12-31 0.75 0.81 0.66 12.00
DB:1FW Past Financials Data
Date (Data in CNY Millions) EPS *
2018-12-31 0.52
2018-09-30 0.44
2018-06-30 0.35
2018-03-31 0.29
2017-12-31 0.24
2017-09-30 0.17
2017-06-30 0.15
2017-03-31 0.15
2016-12-31 0.15
2016-09-30 0.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • WuXi Biologics (Cayman) is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess WuXi Biologics (Cayman)'s future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
WuXi Biologics (Cayman) has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has WuXi Biologics (Cayman) performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare WuXi Biologics (Cayman)'s growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • WuXi Biologics (Cayman) has delivered over 20% year on year earnings growth in the past 5 years.
  • WuXi Biologics (Cayman)'s 1-year earnings growth exceeds its 5-year average (149.6% vs 55%)
  • WuXi Biologics (Cayman)'s earnings growth has exceeded the Europe Life Sciences industry average in the past year (149.6% vs 14.8%).
Earnings and Revenue History
WuXi Biologics (Cayman)'s revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from WuXi Biologics (Cayman) Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1FW Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2,534.45 630.59 326.10 169.29
2018-09-30 2,276.81 520.30 272.05 131.79
2018-06-30 2,019.17 410.00 204.25 94.29
2018-03-31 1,819.00 331.31 182.95 84.38
2017-12-31 1,618.83 252.63 175.39 74.48
2017-09-30 1,428.90 177.27 155.34 65.96
2017-06-30 1,232.94 149.44 127.88 59.55
2017-03-31 1,110.98 145.27 118.90 56.42
2016-12-31 989.03 141.10 109.93 53.28
2016-09-30 888.98 171.04 100.50 61.46
2015-12-31 557.04 44.51 85.67 39.74
2014-12-31 331.85 41.98 48.17 35.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • WuXi Biologics (Cayman) has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • WuXi Biologics (Cayman) used its assets less efficiently than the Europe Life Sciences industry average last year based on Return on Assets.
  • WuXi Biologics (Cayman)'s use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess WuXi Biologics (Cayman)'s performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
WuXi Biologics (Cayman) has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is WuXi Biologics (Cayman)'s financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up WuXi Biologics (Cayman)'s finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • WuXi Biologics (Cayman) is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • WuXi Biologics (Cayman)'s cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of WuXi Biologics (Cayman)'s finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • WuXi Biologics (Cayman) has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from WuXi Biologics (Cayman) Company Filings, last reported 4 months ago.

DB:1FW Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 7,994.23 0.00 4,084.40
2018-09-30 7,994.23 0.00 4,084.40
2018-06-30 7,519.56 0.00 4,371.95
2018-03-31 7,519.56 0.00 4,371.95
2017-12-31 4,024.36 0.00 2,060.00
2017-09-30 4,024.36 0.00 2,060.00
2017-06-30 3,829.51 1,244.24 3,619.78
2017-03-31 3,829.51 1,244.24 3,619.78
2016-12-31 270.47 1,129.44 169.10
2016-09-30 253.73 1,028.43 171.95
2015-12-31 146.00 455.86 158.23
2014-12-31 371.83 55.41 5.95
  • WuXi Biologics (Cayman) has no debt.
  • WuXi Biologics (Cayman) currently has no debt however we can't compare to 5 years ago as we have no data for that period.
  • WuXi Biologics (Cayman) has no debt, it does not need to be covered by operating cash flow.
  • WuXi Biologics (Cayman) has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess WuXi Biologics (Cayman)'s financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. WuXi Biologics (Cayman) has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is WuXi Biologics (Cayman)'s current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from WuXi Biologics (Cayman) dividends. Estimated to be 0% next year.
If you bought €2,000 of WuXi Biologics (Cayman) shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate WuXi Biologics (Cayman)'s dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate WuXi Biologics (Cayman)'s dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1FW Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 0.8%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1FW Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as WuXi Biologics (Cayman) has not reported any payouts.
  • Unable to verify if WuXi Biologics (Cayman)'s dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of WuXi Biologics (Cayman)'s earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as WuXi Biologics (Cayman) has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of WuXi Biologics (Cayman)'s dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess WuXi Biologics (Cayman)'s dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can WuXi Biologics (Cayman) afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. WuXi Biologics (Cayman) has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of WuXi Biologics (Cayman)'s salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Chen
COMPENSATION CN¥23,697,000
AGE 45
TENURE AS CEO 3.3 years
CEO Bio

Dr. Zhisheng Chen, also known as Chris, has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr. Chen is primarily responsible for the overall management of the business of WuXi Biologics (Cayman) Inc. From June 2011 to January 2016, he served as a senior vice president of WXAT Shanghai. He was primarily engaged in the contract development and manufacturing of bio-pharmaceuticals and small molecules. He was responsible for the management of biologics development and manufacturing. From August 2008 to June 2011, he served as the chief operating officer of Shanghai Celgen Bio-Pharmaceutical Co., Ltd. He was primarily engaged in biologics development, commercial manufacturing and marketing and was responsible for the development, manufacturing and quality control of biologics. From November 2005 to August 2008, he served as a director and senior engineering consultant of Eli Lilly. He was primarily engaged in discovering and manufacturing of medicines and was responsible for running a clinical manufacturing facility and providing technical guidance to biologics development and manufacturing. From June 2000 to November 2005, he served as a process engineer and manager of Merck & Co. Inc. He was primarily engaged in developing and sales of pharmaceuticals and was responsible for providing technical support and trouble-shooting manufacturing issues of biologics and recombinant vaccines. Dr. Chen obtained a bachelor’s degree in chemical engineering from Tsinghua University in June 1994 and a Ph.D. degree in chemical engineering from University of Delaware in June 2000.

CEO Compensation
  • Chris's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Chris's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the WuXi Biologics (Cayman) management team in years:

2.3
Average Tenure
54
Average Age
  • The tenure for the WuXi Biologics (Cayman) management team is about average.
Management Team

Chris Chen

TITLE
CEO & Executive Director
COMPENSATION
CN¥24M
AGE
45
TENURE
3.3 yrs

Weichang Zhou

TITLE
CTO, Senior VP & Executive Director
COMPENSATION
CN¥6M
AGE
54
TENURE
2.5 yrs

Christine Lu-Wong

TITLE
Chief Financial Officer
AGE
49
TENURE
3.3 yrs

Zhiling Ji

TITLE
Head of Legal Department

Jing Li

TITLE
Senior Vice President
AGE
46
TENURE
2.6 yrs

Jian Dong

TITLE
Senior Vice President
AGE
54
TENURE
0.9 yrs

Chiang Syin

TITLE
Chief Quality Officer
AGE
63
TENURE
1.3 yrs

Patsy Cheng

TITLE
Joint Company Secretary
AGE
60
TENURE
2.1 yrs

Yue Huang

TITLE
Joint Company Secretary
TENURE
0.5 yrs
Board of Directors Tenure

Average tenure and age of the WuXi Biologics (Cayman) board of directors in years:

3
Average Tenure
54.5
Average Age
  • The tenure for the WuXi Biologics (Cayman) board of directors is about average.
Board of Directors

Ge Li

TITLE
Founder & Chairman
AGE
51
TENURE
5.3 yrs

Chris Chen

TITLE
CEO & Executive Director
COMPENSATION
CN¥24M
AGE
45
TENURE
5.3 yrs

Weichang Zhou

TITLE
CTO, Senior VP & Executive Director
COMPENSATION
CN¥6M
AGE
54
TENURE
3 yrs

William Robert Keller

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥379K
AGE
70
TENURE
2 yrs

Walter Kwauk

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥379K
AGE
65
TENURE
2 yrs

Pete Schultz

TITLE
Chair of Scientific Advisory Board
AGE
61
TENURE
1.3 yrs

Ed Hu

TITLE
Non-Executive Director
AGE
55
TENURE
5.3 yrs

Yibing Wu

TITLE
Non-Executive Director
AGE
50
TENURE
3 yrs

Yanling Cao

TITLE
Non-Executive Director
AGE
34
TENURE
3 yrs

Felix Fong

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥379K
AGE
67
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • WuXi Biologics (Cayman) insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
06. May 19 Sell Xiaozhong Liu Individual 30. Apr 19 30. Apr 19 -3,000 €9.10 €-27,314
08. May 19 Sell J.P. Morgan Asset Management, Inc. Company 03. May 19 03. May 19 -94,787 €9.47 €-897,639
08. May 19 Sell Xiaozhong Liu Individual 06. May 19 06. May 19 -97,000 €9.27 €-898,730
25. Apr 19 Sell Xiaozhong Liu Individual 18. Apr 19 18. Apr 19 -53,500 €9.48 €-507,386
25. Apr 19 Sell Zhaohui Zhang Individual 18. Apr 19 18. Apr 19 -53,000 €9.48 €-502,649
25. Apr 19 Sell Xiaozhong Liu Individual 23. Apr 19 23. Apr 19 -23,000 €9.58 €-220,383
25. Apr 19 Sell Zhaohui Zhang Individual 23. Apr 19 23. Apr 19 -24,000 €9.58 €-230,008
23. Apr 19 Sell Xiaozhong Liu Individual 17. Apr 19 17. Apr 19 -31,500 €9.33 €-294,039
23. Apr 19 Sell Zhaohui Zhang Individual 17. Apr 19 17. Apr 19 -31,000 €9.33 €-289,352
17. Apr 19 Sell Xiaozhong Liu Individual 15. Apr 19 15. Apr 19 -23,000 €9.32 €-214,433
17. Apr 19 Sell Zhaohui Zhang Individual 15. Apr 19 15. Apr 19 -24,000 €9.33 €-223,907
16. Apr 19 Sell Xiaozhong Liu Individual 12. Apr 19 12. Apr 19 -200,000 €9.32 €-1,864,404
16. Apr 19 Sell Zhaohui Zhang Individual 12. Apr 19 12. Apr 19 -200,000 €9.32 €-1,864,257
15. Apr 19 Sell Xiaozhong Liu Individual 11. Apr 19 11. Apr 19 -150,000 €9.32 €-1,397,255
15. Apr 19 Sell Zhaohui Zhang Individual 11. Apr 19 11. Apr 19 -150,000 €9.32 €-1,397,255
12. Apr 19 Sell Xiaozhong Liu Individual 10. Apr 19 10. Apr 19 -51,500 €9.12 €-469,459
12. Apr 19 Sell Zhaohui Zhang Individual 10. Apr 19 10. Apr 19 -49,000 €9.12 €-446,721
10. Apr 19 Sell Xiaozhong Liu Individual 09. Apr 19 09. Apr 19 -46,000 €9.15 €-420,727
10. Apr 19 Sell Zhaohui Zhang Individual 09. Apr 19 09. Apr 19 -48,000 €9.14 €-438,800
28. Mar 19 Sell Wuxi Biologics Holdings Limited Company 25. Mar 19 25. Mar 19 -52,000,000 €8.67 €-451,030,888
27. Mar 19 Sell Zhaohui Zhang Individual 22. Mar 19 22. Mar 19 -36,000 €9.50 €-341,967
04. Mar 19 Buy William Robert Keller Individual 01. Feb 19 01. Feb 19 5,500 €7.71 €42,395
04. Mar 19 Sell William Robert Keller Individual 01. Mar 19 01. Mar 19 -5,500 €8.26 €-45,454
15. Jan 19 Buy J.P. Morgan Asset Management, Inc. Company 10. Jan 19 10. Jan 19 718,646 €6.37 €4,579,981
10. Jan 19 Sell JPMorgan Chase & Co, Brokerage and Securities Investments Company 07. Jan 19 07. Jan 19 -770,132 €5.74 €-4,421,693
10. Jan 19 Sell JPMorgan Chase & Co, Private Banking and Investment Banking Investments Company 07. Jan 19 07. Jan 19 -9,500 €5.74 €-54,544
10. Jan 19 Sell J.P. Morgan Asset Management, Inc. Company 07. Jan 19 07. Jan 19 -1,500 €5.74 €-8,612
10. Jan 19 Buy J.P. Morgan Asset Management, Inc. Company 07. Jan 19 07. Jan 19 90,000 €5.74 €516,733
09. Jan 19 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 04. Jan 19 04. Jan 19 838,337 €5.44 €4,557,525
09. Jan 19 Buy JPMorgan Chase & Co, Private Banking and Investment Banking Investments Company 04. Jan 19 04. Jan 19 7,500 €5.44 €40,773
09. Jan 19 Sell J.P. Morgan Asset Management, Inc. Company 04. Jan 19 04. Jan 19 -7,500 €5.44 €-40,773
08. Jan 19 Sell J.P. Morgan Asset Management, Inc. Company 03. Jan 19 03. Jan 19 -1,027,248 €5.15 €-5,289,709
03. Jan 19 Buy J.P. Morgan Asset Management, Inc. Company 31. Dec 18 31. Dec 18 2,970,856 €5.73 €17,016,256
27. Jun 18 Sell Wuxi Biologics Holdings Limited Company 22. Jun 18 22. Jun 18 -50,000,000 €8.68 €-433,799,319
X
Management checks
We assess WuXi Biologics (Cayman)'s management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. WuXi Biologics (Cayman) has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

WuXi Biologics (Cayman) Inc., an investment holding company, provides discovery, research, development, and manufacturing of biologics services. It offers clinical and commercial manufacturing, assay, formulation and process development, assay and process validation, protein, monoclonal antibodies and cGMP drug substances, lot release testing, stability studies, drug product formulation, fill and finish, and regulatory support services. The company also provides consultation services for biopharmaceutical technology, sales and marketing, and international sales contracting service; and produces and sells medicals. It serves pharmaceutical and biotechnology companies. It has a strategic partnerships with Inhibrx Inc., ABL Bio Corporation of Korea, Brii Biosciences, CANbridge, and AC Immune SA; and strategic collaboration with Oxford BioTherapeutics. The company was founded in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.

Details
Name: WuXi Biologics (Cayman) Inc.
1FW
Exchange: DB
Founded: 2014
HK$9,880,093,591
1,229,921,022
Website: http://www.wuxibiologics.com.cn
Address: WuXi Biologics (Cayman) Inc.
No. 108, Meiliang Road,
Mashan,
Wuxi,
Jiangsu Province, 214092,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 2269 Ordinary Shares The Stock Exchange of Hong Kong Ltd. HK HKD 13. Jun 2017
OTCPK WXIB.F Ordinary Shares Pink Sheets LLC US USD 13. Jun 2017
DB 1FW Ordinary Shares Deutsche Boerse AG DE EUR 13. Jun 2017
OTCPK WXXW.Y UNSPONSORD ADR Pink Sheets LLC US USD 12. Sep 2017
Number of employees
Current staff
Staff numbers
4,141
WuXi Biologics (Cayman) employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/21 22:43
End of day share price update: 2019/05/21 00:00
Last estimates confirmation: 2019/05/21
Last earnings filing: 2019/04/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.